Innoviva Inc. To Present At Morgan Stanley Global Healthcare Conference And Rodman & Renshaw 19th Annual Global Investment Conference

BRISBANE, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ:INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will be presenting at two conferences in New York on Tuesday, September 13. The details are as follows:

Rodman & Renshaw 18th Annual Global Investment Conference
New York Palace Hotel
Tuesday, September 13, 9:10 a.m. EDT
Webcast Link (archived for 90 days): Rodman Innoviva Webcast

Morgan Stanley Global Healthcare Conference
Tuesday, September 13 at 2:55 p.m. EDT
Grand Hyatt Hotel
Webcast (archived for 90 days): Morgan Stanley Innoviva Webcast

About Innoviva

Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc. For more information, please visit Innoviva's website at www.inva.com.

ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

Contacts

Innoviva
Eric d'Esparbes, 650-238-9640
Senior Vice President and Chief Financial Officer
investor.relations@inva.com

Back to news